Treosulfan chemo for myeloma before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether the chemotherapy medicine treosulfan (Trecondi® Ideogen) works well and is safe for people with myeloma who are moving on to high-dose chemotherapy plus their own stem cell transplant. It may help strengthen the transplant “conditioning” treatment before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have myeloma and have finished standard first treatment (induction), and you may still qualify if you needed an extra induction type for resistant disease
- Your doctors think you are healthy enough for high-dose chemotherapy plus your own stem cell transplant (called autologous stem cell transplantation)
- You are 18–75 years old
- Your heart function is strong enough: a recent heart scan shows LVEF at least 40%
- Your kidney function is adequate: creatinine clearance at least 35 ml/min
- You can’t have certain recent or active serious problems like uncontrolled infection, major bleeding problems, or other active cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specific chemotherapy combination (thiotepa and melphalan) given before a stem cell transplant to treat multiple myeloma. The study compares this approach to help doctors understand if it improves outcomes for patients whose myeloma hasn't fully responded to initial treatment.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This Phase 2 trial tests whether a combination of anti-myeloma medicines given before stem cell transplant works well and is safe for people with multiple myeloma who also have kidney problems. It may help control the myeloma and prepare you for the transplant.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.